Psilera’s New Compounds Show Potential for Significant Treatment Improvement in Depression and Neurodegenerative Disorders
PSIL-001 and PSIL-002 show promising antidepressant effects without hallucinations while having improved learning and memory tendencies over a psilocybin mimic TAMPA, Fla., Aug. 10, 2022 /PRNewswire/ — Psilera Inc. (“Psilera”), a biopharmaceutical company optimizing next-generation…
Comments Off on Psilera’s New Compounds Show Potential for Significant Treatment Improvement in Depression and Neurodegenerative Disorders